Tags

Type your tag names separated by a space and hit enter

Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia.
Altern Med Rev. 2004 Dec; 9(4):420-8.AM

Abstract

OBJECTIVE

To assess the effects of krill oil on blood lipids, specifically total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL).

METHODS

A multi-center, three-month, prospective, randomized study followed by a three-month, controlled follow-up of patients treated with 1 g and 1.5 g krill oil daily. Patients with hyperlipidemia able to maintain a healthy diet and with blood cholesterol levels between 194 and 348 mg per dL were eligible for enrollment in the trial. A sample size of 120 patients (30 patients per group) was randomly assigned to one of four groups. Group A received krill oil at a body mass index (BMI)-dependent daily dosage of 2-3 g daily. Patients in Group B were given 1-1.5 g krill oil daily, and Group C was given fish oil containing 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) per gram of oil at a dose of 3 g daily. Group D was given a placebo containing microcrystalline cellulose. The krill oil used in this study was Neptune Krill Oil, provided by Neptune Technologies and Bioresources, Laval, Quebec, Canada.

OUTCOME MEASURES

Primary parameters tested (baseline and 90-day visit) were total blood cholesterol, triglycerides, LDL, HDL, and glucose.

RESULTS

Krill oil 1-3 g per day (BMI-dependent) was found to be effective for the reduction of glucose, total cholesterol, triglycerides, LDL, and HDL, compared to both fish oil and placebo.

CONCLUSIONS

The results of the present study demonstrate within high levels of confidence that krill oil is effective for the management of hyperlipidemia by significantly reducing total cholesterol, LDL, and triglycerides, and increasing HDL levels. At lower and equal doses, krill oil was significantly more effective than fish oil for the reduction of glucose, triglycerides, and LDL levels.

Authors+Show Affiliations

Department of Internal Medicine, McGill University, Montreal, Quebec, Canada.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15656713

Citation

Bunea, Ruxandra, et al. "Evaluation of the Effects of Neptune Krill Oil On the Clinical Course of Hyperlipidemia." Alternative Medicine Review : a Journal of Clinical Therapeutic, vol. 9, no. 4, 2004, pp. 420-8.
Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev. 2004;9(4):420-8.
Bunea, R., El Farrah, K., & Deutsch, L. (2004). Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Alternative Medicine Review : a Journal of Clinical Therapeutic, 9(4), 420-8.
Bunea R, El Farrah K, Deutsch L. Evaluation of the Effects of Neptune Krill Oil On the Clinical Course of Hyperlipidemia. Altern Med Rev. 2004;9(4):420-8. PubMed PMID: 15656713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. AU - Bunea,Ruxandra, AU - El Farrah,Khassan, AU - Deutsch,Luisa, PY - 2005/1/20/pubmed PY - 2005/2/23/medline PY - 2005/1/20/entrez SP - 420 EP - 8 JF - Alternative medicine review : a journal of clinical therapeutic JO - Altern Med Rev VL - 9 IS - 4 N2 - OBJECTIVE: To assess the effects of krill oil on blood lipids, specifically total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). METHODS: A multi-center, three-month, prospective, randomized study followed by a three-month, controlled follow-up of patients treated with 1 g and 1.5 g krill oil daily. Patients with hyperlipidemia able to maintain a healthy diet and with blood cholesterol levels between 194 and 348 mg per dL were eligible for enrollment in the trial. A sample size of 120 patients (30 patients per group) was randomly assigned to one of four groups. Group A received krill oil at a body mass index (BMI)-dependent daily dosage of 2-3 g daily. Patients in Group B were given 1-1.5 g krill oil daily, and Group C was given fish oil containing 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) per gram of oil at a dose of 3 g daily. Group D was given a placebo containing microcrystalline cellulose. The krill oil used in this study was Neptune Krill Oil, provided by Neptune Technologies and Bioresources, Laval, Quebec, Canada. OUTCOME MEASURES: Primary parameters tested (baseline and 90-day visit) were total blood cholesterol, triglycerides, LDL, HDL, and glucose. RESULTS: Krill oil 1-3 g per day (BMI-dependent) was found to be effective for the reduction of glucose, total cholesterol, triglycerides, LDL, and HDL, compared to both fish oil and placebo. CONCLUSIONS: The results of the present study demonstrate within high levels of confidence that krill oil is effective for the management of hyperlipidemia by significantly reducing total cholesterol, LDL, and triglycerides, and increasing HDL levels. At lower and equal doses, krill oil was significantly more effective than fish oil for the reduction of glucose, triglycerides, and LDL levels. SN - 1089-5159 UR - https://www.unboundmedicine.com/medline/citation/15656713/Evaluation_of_the_effects_of_Neptune_Krill_Oil_on_the_clinical_course_of_hyperlipidemia_ L2 - http://archive.foundationalmedicinereview.com/publications/9/4/420.pdf DB - PRIME DP - Unbound Medicine ER -